BeiGene
BGNE
#963
Rank
โ‚ฌ19.32 B
Marketcap
170,29ย โ‚ฌ
Share price
1.02%
Change (1 day)
5.83%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of September 2024 : โ‚ฌ2.60 Billion

According to BeiGene 's latest financial reports the company has โ‚ฌ2.60 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31โ‚ฌ2.87 B-32.08%
2022-12-31โ‚ฌ4.22 B-27.65%
2021-12-31โ‚ฌ5.84 B54.54%
2020-12-31โ‚ฌ3.78 B331.01%
2019-12-31โ‚ฌ0.87 B-43.66%
2018-12-31โ‚ฌ1.55 B123.09%
2017-12-31โ‚ฌ0.69 B99.42%
2016-12-31โ‚ฌ0.35 B280.87%
2015-12-31โ‚ฌ91.9 M151.77%
2014-12-31โ‚ฌ36.5 M1184.02%
2013-12-31โ‚ฌ2.84 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
โ‚ฌ15.81 M-99.39%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.39 B-84.96%๐Ÿ‡บ๐Ÿ‡ธ USA